Financial Contrast: Inogen (NASDAQ:INGN) & Pressure BioSciences (OTCMKTS:PBIO)

Inogen (NASDAQ:INGN) and Pressure BioSciences (OTCMKTS:PBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Earnings & Valuation

This table compares Inogen and Pressure BioSciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$335.70 million	0.69	-$35.89 million	($1.06)	-8.09
Pressure BioSciences	$1.98 million	0.01	-$29.31 million	($0.96)	0.00

Pressure BioSciences has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Pressure BioSciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Inogen and Pressure BioSciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inogen	-7.58%	-13.77%	-8.52%
Pressure BioSciences	N/A	N/A	N/A

Insider & Institutional Ownership

89.9% of Inogen shares are owned by institutional investors. Comparatively, 0.0% of Pressure BioSciences shares are owned by institutional investors. 1.5% of Inogen shares are owned by company insiders. Comparatively, 10.8% of Pressure BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Inogen has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Pressure BioSciences has a beta of -0.22, indicating that its stock price is 122% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Inogen and Pressure BioSciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1	1	1	0	2.00
Pressure BioSciences	0	0	0	0	0.00

Inogen currently has a consensus price target of $11.00, suggesting a potential upside of 28.21%. Given Inogen’s stronger consensus rating and higher possible upside, research analysts plainly believe Inogen is more favorable than Pressure BioSciences.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

About Pressure BioSciences

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.